Elvina Almuradova: Survival outcomes for ERBB2-positive MBC patients with brain metastases
Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology (IEO), shared an article by Emanuela Ferraro, et al. on LinkedIn:
“A recent study from Memorial Sloan Kettering Cancer Center, published in JAMA Network Open, provides crucial insights into survival outcomes for ERBB2-positive metastatic breast cancer (MBC) patients with brain metastases.
In this cohort study of 274 patients with ERBB2+ MBC and brain metastasis, CNS progression was the most common cause of death. Despite high rates of local therapy, patients with CNS-only disease experienced longer survival than those with concomitant extracranial metastasis but still had significant CNS-related mortality. ‘
More effective CNS-penetrant systemic therapies are urgently needed. As new anti-ERBB2 and other anticancer agents emerge, clinical trials should include patients with CNS disease to evaluate intracranial efficacy from the early stages of drug development.
Additionally, trial designs should incorporate end points that specifically address CNS outcomes, including CNS-related mortality.”
Survival Among Patients With ERBB2-Positive Metastatic Breast Cancer and Central Nervous System Disease.
Authors: Emanuela Ferraro, et al.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023